Invention Grant
US08778894B2 Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism
有权
木犀草素和diosmin / diosmetin作为治疗自闭症的新型STAT3抑制剂
- Patent Title: Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism
- Patent Title (中): 木犀草素和diosmin / diosmetin作为治疗自闭症的新型STAT3抑制剂
-
Application No.: US14046381Application Date: 2013-10-04
-
Publication No.: US08778894B2Publication Date: 2014-07-15
- Inventor: Jun Tan , Deyan Luo , Roland Douglas Shytle
- Applicant: Jun Tan , Deyan Luo , Roland Douglas Shytle
- Applicant Address: US FL Tampa
- Assignee: University of South Florida
- Current Assignee: University of South Florida
- Current Assignee Address: US FL Tampa
- Agency: Smith & Hopen, P. A.
- Agent Michele L. Lawson
- Main IPC: A01N43/04
- IPC: A01N43/04 ; A61K31/70 ; A01N43/16 ; A61K31/35
Abstract:
The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.
Public/Granted literature
- US20140038913A1 LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM Public/Granted day:2014-02-06
Information query
IPC分类:
